Prof. Yan Xiaoyu

About me

Yan Xiaoyu 閆曉宇

Assistant Professor
School of Pharmacy
Faculty of Medicine
The Chinese University of Hong Kong

Tel: (852) 3943 5012
Fax:(852) 2603 5295
Email: xiaoyuyan@cuhk.edu.hk

Personal Details

Xiaoyu Yan received his Bachelor’s and Master’s degree from Shenyang Pharmaceutical University, China. He also received a Master’s degree in pharmaceutical sciences from University of Saskatchewan, Canada. He obtained his PhD in 2012 from Department of Pharmaceutical Sciences, University at Buffalo (SUNY). After his PhD, he worked as a clinical pharmacometrician/pharmacologist at Janssen Research & Development (Johnson & Johnson) and Regeneron Pharmaceuticals, USA.

During his time in pharmaceutical industry, Xiaoyu applied model informed drug development approaches to help the development team not only better understand disease and target, but also find the right dose for the right patient at right time. He has contributed to the global approval of several new therapies for diseases in various areas, such as oncology, immunology, cardiovascular, and neuroscience.

Xiaoyu joined the School of Pharmacy at the Chinese University of Hong Kong in September 2018. His research interests are focused on the pharmacokinetics and pharmacodynamics of therapeutic biologics, and utilization of modeling and simulation approaches to optimize drug therapy and develop new treatment strategy.

*Seeking self-motivated MPhil/PhD candidates*.
Please contact Dr Yan (xiaoyuyan@cuhk.edu.hk) for more information. 

Research

Research Interests

Xiaoyu’s current research is focused on the development of new therapies for anemic patients demonstrating resistance to erythropoiesis-stimulating agents (ESAs). ESAs is a class of therapeutic proteins functioning as erythropoietin receptor (EPOR) agonists. They stimulate the production of red blood cells by binding to EPOR on erythroid cells in bone marrow, and stimulate their proliferation and differentiation.

ESAs has transformed the way of managing the anemia in patients with chronic kidney disease (CKD), who may need blood transfusion otherwise. Recombinant human erythropoietin (rHuEPO) is the first approved ESA by US FDA in 1989 to treat anemia associated with CKD. However, up to 10% of anemic patients failed to show a satisfactory response to rHuEPO, and still require blood transfusion eventually. This phenomenon was named EPO resistance. The EPO resistance is also associated with increased risk of death or cardiovascular events.

Xiaoyu’s previous work suggested the rHuEPO treatment can induce erythroid precursor pool depletion, which may contribute to EPO resistance. Accordingly, his current work is to further the understanding role of precursor depletion in EPO resistance, and look for new therapeutic strategy that may alleviate rHuEPO induced precursor depletion. This work may provide new treatment option for anemic patients showing EPO resistance, and reduce their transfusion burden.

Teaching

Teaching

  • PHAR5130 Overview of Drug Development
  • PHAR2220 Biopharmaceutics and Pharmacokinetics
  • GENA1113 General Education

Publications

Representative Publications

  1. Willmann S, Zhang L, Frede M, Kubitza D, Mueck W, Schmidt S, Solms A, Yan X, Garmann D. Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations. CPT Pharmacometrics Syst Pharmacol 2018; 7: 309-320
  2. Yan X, Clemens PL, Puchalski T, et al. Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet 2018; 57:529-538
  3. Xu X, Schecter J, Jansson R, and Yan X. Response to “The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma”. Clin. Pharmacol. Ther 2017; 102:905
  4. Casneuf T, Xu X, Adams H, Chui C, Khan I, Ahmadi T, Yan X, Lonial S et al. Pharmacodynamic Effects of Daratumumab on Natural Killer Cells and Outcomes in Relapsed Refractory Multiple Myeloma. BLOOD ADV 2017; 1:2105-2114
  5. Clemens PL, Yan X, Puchalski T, et al. Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. Clin Pharmacokinet 2017; 56:915-924
  6. Zhang L, Yan X, Nobi S, et al. Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach. Clin Drug Investig 2017; 37(3):273-283.
  7. Xu X, Yan X, Puchalski T, et al. Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma. Clin. Pharmacol. Ther 2017; 101:721-724
  8. Yan X and Krzyzanski W. Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents. CPT Pharmacometrics Syst Pharmacol 2013; 2:e62
  9. Yan X, Ait-Oudhia S, Krzyzanski W. Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness. Pharm Res 2013; 30:1026-36
  10. Yan X, Chen Y, Krzyzanski W. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J Pharmacokinet Pharmacodyn 2012; 39:543-60
  11. Yan X and Krzyzanski W. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. J Pharmacokinet Pharmacodyn 2012; 39:141-6.
  12. Yan X, Lowe P, Fink M, et al. Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human epoetin alfa and the biosimilar HX575. J Clin Pharmacol 2011; 52(11):1624-44
  13. Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 2010; 37:25-47

More Publications

Supplementary Information

Awards

  • Janssen R&D, Innovation Leadership Awards, 2016
  • Janssen R&D, Innovation Leadership Awards, 2015
  • Janssen R&D, Innovation Leadership Awards, 2014
  • McKeen Cattell Memorial Award, American College of Clinical Pharmacology (ACCP) Recognition Award, Washington, DC 2013
  • American Society for Clinical Pharmacology & Therapeutics (ASCPT) Presidential Trainee Award, ASCPT Annual Meeting, Indianapolis, IN 2013
  • Graduate Student Symposium Award PPDM/CPTR, American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Washington, DC, 2011
  • Travel Award by AAPS Executive Council, AAPS Annual Meeting, New Orleans, LA, 2010
  • Pfizer Canada Centennial Pharmacy Research Award, Saskatoon, Canada 2006

Professional Memberships

  • American Association of Pharmaceutical Scientists
  • American College of Clinical Pharmacology
  • International Society of Pharmacometrics (ISoP)
  • American Society Clinical Pharmacology & Therapeutics

Comments are closed